Significant obesity-associated gene expression changes occur in the stomach but not intestines in obese mice

Physiological Reports

Volumn 4, Issue 10, 2016, Pages

  Chen, Jing ^a   Chen, Lihong ^a   Sanseau, Philippe ^a   Freudenberg, Johannes M ^a   Rajpal, Deepak K ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Diet induced changes; Metabolic diseases; Obesity; Obesity mechanisms; Stomach; Transcriptomics

Indexed keywords

ADIPOSE TISSUE; ADVERSE EFFECTS; ANIMAL; C57BL MOUSE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; INTESTINE; LIPID DIET; MALE; METABOLISM; MOUSE; MOUSE MUTANT; OBESITY; PROCEDURES; STOMACH;

ADIPOSE TISSUE; ANIMALS; DIET, HIGH-FAT; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; INTESTINES; MALE; MICE; MICE, INBRED C57BL; MICE, OBESE; OBESITY; STOMACH;

EID: 84971393027     PISSN: None     EISSN: 2051817X     Source Type: Journal    
DOI: 10.14814/phy2.12793     Document Type: Article

References (52)

1. Amland, P. F., R. Jorde, K. E. Giercksky, S. Kildebo, and P. G. Burhol. 1984. Fasting and postprandial serum gastrin levels in obese and slim subjects, and the effects of surgical treatment for obesity on serum gastrin levels. Acta Chir. Scand 150:223-228.
2. Arble, D. M., D. A. Sandoval, and R. J. Seeley. 2015. Mechanisms underlying weight loss and metabolic improvements in rodent models of bariatric surgery. Diabetologia 58:211-220.
3. Bandyopadhyay, G. K., M. Lu, E. Avolio, J. A. Siddiqui, J. R. Gayen, J. Wollam, et al. 2015. Pancreastatin-dependent inflammatory signaling mediates obesity-induced insulin resistance. Diabetes 64:104-116.
4. Birketvedt, G. S., E. Thom, B. Bernersen, and J. Florholmen. 2000. Combination of diet, exercise and intermittent treatment of cimetidine on body weight and maintenance of weight loss. A 42 months follow-up study. Med. Sci. Monit. 6:699-703.
5. Brown, A. C., W. I. Olver, C. J. Donnelly, M. E. May, J. K. Naggert, D. J. Shaffer, et al. 2005. Searching QTL by gene expression: analysis of diabesity. BMC Genet. 6:12.
6. Cremonini, F., M. Camilleri, J. Gonenne, D. Stephens, L. Oenning, K. Baxter, et al. 2005. Effect of somatostatin analog on postprandial satiation in obesity. Obes. Res. 13:1572-1579.
7. Dai, M., P. Wang, A. D. Boyd, G. Kostov, B. Athey, E. G. Jones, et al. 2005. Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res. 33:e175.
8. De Giorgio, M. R., M. Yoshioka, I. Riedl, O. Moreault, R. G. Cherizol, A. A. Shah, et al. 2013. Trefoil factor family member 2 (Tff2) KO mice are protected from high-fat diet-induced obesity. Obesity (Silver Spring) 21:1389-1395.
9. Dimaline, R., B. J. Campbell, F. Watson, A. K. Sandvik, J. Struthers, and P. J. Noble. 1997. Regulated expression of GATA-6 transcription factor in gastric endocrine cells. Gastroenterology 112:1559-1567.
10. +-ATPase. Curr. Opin. Nephrol. Hypertens. 8:597-602.
11. +-ATPase in the apical canalicular membrane of gastric parietal cells. J. Biol. Chem. 284:619-629.
12. Haffer, K. 2012. Effects of novel vaccines on weight loss in diet-induced-obese (DIO) mice. J. Anim. Sci. Biotechnol. 3:21.
13. + channels and gastric acid secretion. Physiology 22:335-341.
14. Hollie, N. I., E. S. Konaniah, C. Goodin, and D. Y. Hui. 2014. Group 1B phospholipase A(2) inactivation suppresses atherosclerosis and metabolic diseases in LDL receptor-deficient mice. Atherosclerosis 234:377-380.
15. Huggins, K. W., A. C. Boileau, and D. Y. Hui. 2002. Protection against diet-induced obesity and obesity-related insulin resistance in Group 1B PLA2-deficient mice. Am. J. Physiol. Endocrinol. Metab. 283:E994-E1001.
16. Hui, D. Y., M. J. Cope, E. D. Labonte, H. T. Chang, J. Shao, E. Goka, et al. 2009. The phospholipase A(2) inhibitor methyl indoxam suppresses diet-induced obesity and glucose intolerance in mice. Br. J. Pharmacol. 157:1263-1269.
17. Irizarry, R. A., B. Hobbs, F. Collin, Y. D. Beazer-Barclay, K. J. Antonellis, U. Scherf, et al. 2003. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4:249-264.
18. Jain, R. N., C. S. Brunkan, C. S. Chew, and L. C. Samuelson. 2006. Gene expression profiling of gastrin target genes in parietal cells. Physiol. Genomics 24:124-132.
19. Kauffmann, A., R. Gentleman, and W. Huber. 2009. arrayQualityMetrics-a bioconductor package for quality assessment of microarray data. Bioinformatics 25:415-416.
20. Kiefer, F. W., M. Zeyda, K. Gollinger, B. Pfau, A. Neuhofer, T. Weichhart, et al. 2010. Neutralization of osteopontin inhibits obesity-induced inflammation and insulin resistance. Diabetes 59:935-946.
21. Labonte, E. D., P. T. Pfluger, J. G. Cash, D. G. Kuhel, J. C. Roja, D. P. Magness, et al. 2010. Postprandial lysophospholipid suppresses hepatic fatty acid oxidation: the molecular link between group 1B phospholipase A2 and diet-induced obesity. FASEB J. 24:2516-2524.
22. Lancha, A., A. Rodriguez, V. Catalan, S. Becerril, N. Sainz, B. Ramirez, et al. 2014. Osteopontin deletion prevents the development of obesity and hepatic steatosis via impaired adipose tissue matrix remodeling and reduced inflammation and fibrosis in adipose tissue and liver in mice. PLoS ONE 9:e98398.
23. Lau, S. K., L. M. Weiss, and P. G. Chu. 2004. Differential expression of MUC1, MUC2, and MUC5AC in carcinomas of various sites: an immunohistochemical study. Am. J. Clin. Pathol. 122:61-69.
24. Leung, W. K., J. Yu, F. K. Chan, K. F. To, M. W. Chan, M. P. Ebert, et al. 2002. Expression of trefoil peptides (TFF1, TFF2, and TFF3) in gastric carcinomas, intestinal metaplasia, and non-neoplastic gastric tissues. J. Pathol. 197:582-588.
25. Leung-Theung-Long, S. P., E. Roulet, P. Clerc, C. Escrieut, S. Marchal-Victorion, B. Ritz-Laser, et al. 2005. Essential interaction of Egr-1 at an islet specific response element for basal and gastrin-dependent glucagon gene transactivation in pancreatic alpha cells. J. Biol. Chem. 280:7976-7984.
26. Li, Z., G. Xu, Y. Li, J. Zhao, M. W. Mulholland, and W. Zhang. 2012. mTOR-dependent modulation of gastric nesfatin-1/NUCB2. Cell. Physiol. Biochem. 29:493-500.
27. Madsbad, S. 2014. The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications. Diabetes Obes. Metab. 16:9-21.
28. Maggard-Gibbons, M., M. Maglione, and M. Livhits. 2013. Bariatric surgery for weight loss and glycemic control in nonmorbidly obese adults with diabetes: a systematic review. JAMA 309:2250-2261.
29. Melissas, J., E. Kampitakis, G. Schoretsanitis, J. Mouzas, E. Kouroumalis, and D. D. Tsiftsis. 2002. Does reduction in gastric acid secretion in bariatric surgery increase diet-induced thermogenesis? Obes. Surg. 12:399-403.
30. Mingrone, G., and L. Castagneto-Gissey. 2009. Mechanisms of early improvement/resolution of type 2 diabetes after bariatric surgery. Diabetes Metab. 35:518-523.
31. Morton, A. P., P. J. Hanson, and G. J. Dockray. 1985. Elevated serum and antral gastrin in obese (ob/ob) mice. Gastroenterology 88:945-950.
32. Nies, A. T., U. Hofmann, C. Resch, E. Schaeffeler, M. Rius, and M. Schwab. 2011. Proton pump inhibitors inhibit metformin uptake by Organic Cation Transporters (OCTs). PLoS ONE 6:e22163.
33. Nomiyama, T., D. Perez-Tilve, D. Ogawa, F. Gizard, Y. Zhao, E. B. Heywood, et al. 2007. Osteopontin mediates obesity-induced adipose tissue macrophage infiltration and insulin resistance in mice. J. Clin. Invest. 117:2877-2888.
34. Patel, R. T., A. P. Shukla, S. M. Ahn, M. Moreira, and F. Rubino. 2014. Surgical control of obesity and diabetes: the role of intestinal vs. gastric mechanisms in the regulation of body weight and glucose homeostasis. Obesity 22:159-169.
35. Pederson, R. A., R. V. Campos, C. B. Chan, A. M. Buchan, M. B. Wheeler, and J. C. Brown. 1989. Gastrin release in obese Zucker rats. Regul. Pept. 24:131-142.
36. Ren, J., Z. Chen, W. Zhang, L. Li, R. Sun, C. Deng, et al. 2011. Increased fat mass and insulin resistance in mice lacking pancreatic lipase-related protein 1. J. Nutr. Biochem. 22:691-698.
37. Ritchie, M. E., B. Phipson, D. Wu, Y. Hu, C. W. Law, W. Shi, et al. 2015. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43:e47.
38. Rubino, F., A. Forgione, D. E. Cummings, M. Vix, D. Gnuli, G. Mingrone, et al. 2006. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of Type 2 diabetes. Ann. Surg. 244:741-749.
39. Rubino, F., S. L. R'bibo, F. del Genio, M. Mazumdar, and T. E. McGraw. 2010. Metabolic surgery: the role of the gastrointestinal tract in diabetes mellitus. Nat. Rev. Endocrinol. 6:102-109.
40. Sasaki, H., M. Nagulesparan, A. Dubois, E. Straus, I. M. Samloff, W. H. Lawrence, et al. 1983. Hypergastrinemia in obese noninsulin-dependent diabetes: a possible reflection of high prevalence of vagal dysfunction. J. Clin. Endocrinol. Metab. 56:744-750.
41. Sato, T., Y. Nakamura, Y. Shiimura, H. Ohgusu, K. Kangawa, and M. Kojima. 2012. Structure, regulation and function of ghrelin. J. Biochem. 151:119-128.
42. Schubert, M. L. 1999. Regulation of gastric acid secretion. Curr. Opin. Gastroenterol. 15:457-462.
43. Shin, J. M., K. Munson, O. Vagin, and G. Sachs. 2009. The gastric HK-ATPase: structure, function, and inhibition. Pflugers Arch. 457:609-622.
44. Stoa-Birketvedt, G., P. N. Paus, R. Ganss, O. C. Ingebretsen, and J. Florholmen. 1998. Cimetidine reduces weight and improves metabolic control in overweight patients with type 2 diabetes. Int. J. Obes. Relat. Metab. Disord. 22:1041-1045.
45. Sun-Wada, G. H., Y. Kamei, Y. Wada, and M. Futai. 2004. Regulatory elements directing gut expression of the GATA 6 gene during mouse early development. J. Biochem. 135:165-169.
46. Waldum, H. L., A. K. Sandvik, E. Brenna, and H. Petersen. 1991. Gastrin-histamine sequence in the regulation of gastric acid secretion. Gut 32:698-701.
47. Wisen, O., S. Rossner, and C. Johansson. 1987. Gastric secretion in massive obesity. Evidence for abnormal response to vagal stimulation. Dig. Dis. Sci. 32:968-972.
48. World Health Organization. 2009. Global health risks: mortality and burden of disease attributable to selected major risks. World Health Organization, Geneva.
49. Yang, Q., T. E. Graham, N. Mody, F. Preitner, O. D. Peroni, J. M. Zabolotny, et al. 2005. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 436:356-362.
50. Yoshikawa, I., M. Nagato, M. Yamasaki, K. Kume, and M. Otsuki. 2009. Long-term treatment with proton pump inhibitor is associated with undesired weight gain. World J. Gastroenterol. 15:4794-4798.
51. Zemany, L., S. Bhanot, O. D. Peroni, S. F. Murray, P. M. Moraes-Vieira, A. Castoldi, et al. 2015. Transthyretin antisense oligonucleotides lower circulating RBP4 levels and improve insulin sensitivity in obese mice. Diabetes 64:1603-1614.
52. Zwirska-Korczala, K., S. J. Konturek, M. Sodowski, M. Wylezol, D. Kuka, P. Sowa, et al. 2007. Basal and postprandial plasma levels of PYY, ghrelin, cholecystokinin, gastrin and insulin in women with moderate and morbid obesity and metabolic syndrome. J. Physiol. Pharmacol. 58(Suppl. 1):13-35.